PMID- 24391751
OWN - NLM
STAT- MEDLINE
DCOM- 20140825
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 12
DP  - 2013
TI  - Cerebral hemodynamics and systemic endothelial function are already impaired in 
      well-controlled type 2 diabetic patients, with short-term disease.
PG  - e83287
LID - 10.1371/journal.pone.0083287 [doi]
LID - e83287
AB  - OBJECTIVE: Impaired cerebral vasomotor reactivity (VMR) and flow-mediated 
      dilation (FMD) were found in selected subgroups of type 2 diabetes mellitus 
      (T2DM) patients with long-term disease. Our study aimed to evaluate cerebral 
      hemodynamics, systemic endothelial function and sympatho-vagal balance in a 
      selected population of well-controlled T2DM patients with short-term disease and 
      without cardiac autonomic neuropathy (CAN). RESEARCH DESIGN AND METHODS: 
      Twenty-six T2DM patients with short-term (4.40+/-4.80 years) and well-controlled 
      (HbA1C = 6.71+/-1.29%) disease, without any complications, treated with diet and/or 
      metformin, were consecutively recruited. Eighteen controls, comparable by sex and 
      age, were enrolled also. RESULTS: FMD and shear rate FMD were found to be reduced 
      in T2DM subjects with short-term disease (8.5% SD 3.5 and 2.5 SD 1.3, 
      respectively) compared to controls (15.4% SD 4.1 and 3.5 SD 1.4; p<.001 and 
      p<.05). T2DM patients also displayed reduced VMR values than controls (39.4% SD 
      12.4 vs 51.7%, SD 15.5; p<.05). Sympatho-vagal balance was not different in T2DM 
      patients compared to healthy subjects. FMD and shear rate FMD did not correlate 
      with VMR in T2DM patients or in controls (p>.05). CONCLUSIONS: In well-controlled 
      T2DM patients with short-term disease cerebral hemodynamics and systemic 
      endothelial function are altered while autonomic balance appeared to be 
      preserved.
FAU - Palazzo, Paola
AU  - Palazzo P
AD  - Department of Neurology, Campus Bio-Medico University, Rome, Italy ; Department 
      of Neurology, S. Giovanni Calibita Fatebenefratelli Hospital, Rome, Italy.
FAU - Maggio, Paola
AU  - Maggio P
AD  - Department of Neurology, Campus Bio-Medico University, Rome, Italy.
FAU - Altavilla, Riccardo
AU  - Altavilla R
AD  - Department of Neurology, Campus Bio-Medico University, Rome, Italy.
FAU - Di Flaviani, Alessandra
AU  - Di Flaviani A
AD  - Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita Fatebenefratelli 
      Hospital, University of Rome Tor Vergata, Rome, Italy.
FAU - Giordani, Ilaria
AU  - Giordani I
AD  - Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita Fatebenefratelli 
      Hospital, University of Rome Tor Vergata, Rome, Italy.
FAU - Malandrucco, Ilaria
AU  - Malandrucco I
AD  - Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita Fatebenefratelli 
      Hospital, University of Rome Tor Vergata, Rome, Italy.
FAU - Picconi, Fabiana
AU  - Picconi F
AD  - Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita Fatebenefratelli 
      Hospital, University of Rome Tor Vergata, Rome, Italy.
FAU - Passarelli, Francesco
AU  - Passarelli F
AD  - Department of Neurology, S. Giovanni Calibita Fatebenefratelli Hospital, Rome, 
      Italy.
FAU - Pasqualetti, Patrizio
AU  - Pasqualetti P
AD  - SeSMIT, Service for Medical Statistics & IT, Fatebenefratelli Association for 
      Research, Isola Tiberina, Rome, Italy.
FAU - Ercolani, Matilde
AU  - Ercolani M
AD  - Department of Neurology, S. Giovanni Calibita Fatebenefratelli Hospital, Rome, 
      Italy.
FAU - Vernieri, Fabrizio
AU  - Vernieri F
AD  - Department of Neurology, Campus Bio-Medico University, Rome, Italy.
FAU - Frontoni, Simona
AU  - Frontoni S
AD  - Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita Fatebenefratelli 
      Hospital, University of Rome Tor Vergata, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20131231
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Autonomic Nervous System/physiopathology
MH  - Case-Control Studies
MH  - Cerebrovascular Circulation/*physiology
MH  - Diabetes Mellitus, Type 2/diet therapy/drug therapy/*physiopathology
MH  - Diet, Diabetic
MH  - Endothelium, Vascular/physiopathology
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Hemodynamics
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Time Factors
MH  - Vasodilation/physiology
MH  - Vasomotor System/physiopathology
PMC - PMC3877017
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/01/07 06:00
MHDA- 2014/08/26 06:00
PMCR- 2013/12/31
CRDT- 2014/01/07 06:00
PHST- 2013/07/30 00:00 [received]
PHST- 2013/11/11 00:00 [accepted]
PHST- 2014/01/07 06:00 [entrez]
PHST- 2014/01/07 06:00 [pubmed]
PHST- 2014/08/26 06:00 [medline]
PHST- 2013/12/31 00:00 [pmc-release]
AID - PONE-D-13-31131 [pii]
AID - 10.1371/journal.pone.0083287 [doi]
PST - epublish
SO  - PLoS One. 2013 Dec 31;8(12):e83287. doi: 10.1371/journal.pone.0083287. 
      eCollection 2013.